Browse complete Kinase Therapeutics: Pipeline Assessment and Commercial Prospects Report
Browse all CCM International Market Research Reports
The number of kinase inhibitors entering clinical development has increased significantly in recent years. In addition to major pharmaceutical and biotech companies, an increasing number of emerging companies are focusing on their development. By 2020, small-molecule kinase inhibitors could generate annual revenues > $25 billion.
This report assesses:
- R&D considerations specific to targeting kinases
- Current kinase inhibitor pipelines
- Commercial successes to date
- Near- and longer-term market outlook
- Corporate activities of firms involved with kinases
Kinases are now firmly established as a major class of drug targets. It was previously thought that kinases would be intractable drug targets due to the presumed need to compete with ATP and the assumption that sufficient selectivity would be unattainable. However, considerable progress has been made in understanding kinases and their function, and the past few years have seen a number of kinase inhibitors reach the market. Imatinib (Novartis’ Gleevec) is currently the most commercially successful, with sales reaching $3.7 billion in 2008. Erlotinib (OSI/Roche’s Tarceva) generated revenues of $1.1 billion the same year.
In recent years, there has been an explosion in the number of kinase inhibitors entering the clinic, and many more are in preclinical development. Kinase Therapeutics: Pipeline Assessment and Commercial Prospects identifies which kinase families and their respective members have attracted the greatest interest for therapeutic development and in which indications these kinases play a physiological or pathophysiological role and thus are most relevant for kinase inhibitor development.
About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
